The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.
N. R. Dickson
No relevant relationships to disclose
S. F. Jones
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
R. K. Ramanathan
No relevant relationships to disclose
G. J. Weiss
No relevant relationships to disclose
J. R. Infante
No relevant relationships to disclose
J. C. Bendell
No relevant relationships to disclose
W. McCulloch
Consultant or Advisory Role - Niiki
D. D. Von Hoff
Research Funding - Niiki